VIDEO: Age ‘not a limiting factor’ of stem cell transplantation in multiple myeloma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO — In this video, Adam Binder, MD, assistant professor at Thomas Jefferson University, discusses an oral abstract presented at the ASH Annual Meeting and Exposition that revealed melphalan conditioning with autologous hematopoietic stem cell transplantation was safe and effective for patients of all ages with multiple myeloma, particularly those aged 70 years or older.

“This is good because we need to think of age not as a limiting factor when considering stem cell transplant in our multiple myeloma patient population,” Binder told HemOnc Today. – by Alaina Tedesco

Reference:

Munshi PN, et al. Abstract 782. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.

Disclosure: Binder reports no relevant financial disclosures.